GlaxoSmithKline (GSK) has announced a new clinical study titled ‘A Phase 2, Multicenter, Open Label, Non-randomized Study to Evaluate the Efficacy and Safety of Extended Dosing of Belantamab Mafodotin ...
Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers Squibb ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback